Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES)

We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.